Myriad Genetics (NASDAQ:MYGN – Get Rating) was upgraded by StockNews.com from a “hold” rating to a “buy” rating in a research note issued on Tuesday. Shares of NASDAQ MYGN opened at $24.44 on Tuesday. The stock has a fifty day moving average price of $25.14 and a 200 day moving average price of $27.24. Myriad […]
StockNews.com initiated coverage on shares of Cancer Genetics (NASDAQ:CGIX – Get Rating) in a research note issued on Sunday. The brokerage set a “sell” rating on the stock. Shares of NASDAQ:CGIX opened at $1.37 on Friday. Cancer Genetics has a one year low of $2.11 and a one year high of $17.50. Cancer Genetics Company […]
Toth Financial Advisory Corp reduced its stake in shares of Fulgent Genetics, Inc. (NASDAQ:FLGT – Get Rating) by 66.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 300 shares of the company’s stock after selling 600 shares […]
TAP Consulting LLC bought a new stake in Fulgent Genetics, Inc. (NASDAQ:FLGT – Get Rating) during the fourth quarter, HoldingsChannel reports. The institutional investor bought 481 shares of the company’s stock, valued at approximately $48,000. Several other institutional investors also recently bought and sold shares of the company. Cim LLC increased its position in shares […]
Fulgent Genetics (NASDAQ:FLGT – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Monday, Zacks.com reports. According to Zacks, “Fulgent Genetics, Inc. is a technology company. It provide genetic testing services to physicians with clinically actionable diagnostic information. The Company’s technology […]